NASDAQ: DERMJourney Medical Corp Stock
$4.02-0.40 (-9.05%)
Updated Apr 15, 2024
DERM Price
$4.02
Fair Value Price
N/A
Market Cap
$80.13M
52 Week Low
$1.02
52 Week High
$8.11
P/E
-19.14x
P/B
3.94x
P/S
1.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$79.18M
Earnings
-$3.85M
Gross Margin
66.3%
Operating Margin
-2.44%
Profit Margin
-4.9%
Debt to Equity
2.78
Operating Cash Flow
$5M
Beta
0.38
Next Earnings
May 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DERM Overview
Journey Medical Corporation develops and commercializes pharmaceuticals to treat dermatological conditions in the U.S. Products include Qbrexza, Accutane, Targadox, Ximino, and Exelderm. Journey Medical also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. Formerly known as Coronado Dermatology, Inc., the company was incorporated in 2014 and is headquartered in Scottsdale, AZ.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DERM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DERM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DERM is poor value based on its book value relative to its share price (3.94x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.03x)
P/B vs Industry Valuation
DERM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DERM due diligence checks available for Premium users.
Be the first to know about important DERM news, forecast changes, insider trades & much more!
DERM News
Valuation
DERM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-19.14x
Industry
49.25x
Market
41.94x
DERM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.94x
Industry
2.03x
DERM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DERM's financial health
Profit margin
Revenue
$15.3M
Net Income
-$2.1M
Profit Margin
-14%
DERM's Earnings (EBIT) of -$1.93M... subscribe to Premium to read more.
Interest Coverage Financials
DERM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$76.8M
Liabilities
$56.5M
Debt to equity
2.78
DERM's short-term assets ($56.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DERM's short-term assets ($56.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DERM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.5M
Investing
$0.0
Financing
$19.2M
DERM's operating cash flow ($5.24M)... subscribe to Premium to read more.
Debt Coverage Financials
DERM vs Pharmaceutical Stocks
Journey Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.